Eli Lilly (NYSE:LLY) and collaboration partner Innovent Biologics (OTCPK:IVBIY) announce that
the China National Medical Products Administration has accepted for
review the supplemental marketing application seeking approval to use
the combination of Tyvyt (sintilimab), Alimta (pemetrexed) and
platinum-based chemo for the first-line treatment of non-squamous
non-small cell lung cancer.
Tyvyt, a PD-1 inhibitor, was approved in China in
December 2018 for patients with relapsed/refractory classical Hodgkin
lymphoma who have received at least two prior lines of chemo.
https://seekingalpha.com/news/3564067-lilly-and-innovent-application-for-triplet-therapy-for-lung-cancer-accepted-in-china
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.